Argenx's big bid to stay ahead
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
The end of the Humira era
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Amgen strikes out for the Horizon
Amgen sees off Sanofi and J&J to clinch the rare disease player for $28bn, ensuring that the M&A year ends with a bang.
Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Novartis’s renaissance gets off to a false start
Leqvio’s launch remains sluggish and tislelizumab looks even more like a dead end in the US.
